Among patients with mild to moderate COVID-19, the asthma drug montelukast did not reduce duration of symptoms, results of the ACTIV-6 trial showed.
As reported in JAMA Network Open, treatment with montelukast (Singulair) did not reduce duration of COVID-19 symptoms in the randomized clinical trial of outpatients with mild to moderate COVID-19. These findings do not support the use of montelukast for the treatment of mild to moderate COVID-19, reported Susanna Naggie, MD, MHS, director of Duke CTSI, and colleagues.
After receiving montelukast or placebo for 14 days, no differences in time to sustained recovery were observed between groups, and the unadjusted median time to sustained recovery was 10 days for both groups. Across the entire study population of the study, researchers did not see a clear benefit.
Naggie and Adrian Hernandez, MD, director of DCRI, are co-principal investigators for ACTIV-6. The leadership team also includes Christopher Lindsell, PhD, director of CTSI Biostatistics and Bioinformatics.